<DOC>
	<DOCNO>NCT02478450</DOCNO>
	<brief_summary>This study non-randomized , open-label , partially blind , sequential cohort , dose-escalation study design obtain preliminary data safety , tolerability , early efficacy Q-Cells® transplantation subject ALS . Following initial cohort receive cell transplant unilaterally lumbar spinal cord , subsequent cohort receive escalate dos transplant unilaterally cervical spinal cord . Subjects outcome measure assessor blind side treatment . The study conduct site extensive clinical experience care patient ALS .</brief_summary>
	<brief_title>Study Investigate Safety Transplantation ( Injection ) Human Glial Restricted Progenitor Cells ( hGRPs ; Q-Cells® ) Into Subjects With Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>This study non-randomized , open-label , partially blind , sequential cohort , dose-escalation study design obtain preliminary data safety , tolerability , early efficacy Q-Cells® transplantation subject ALS . Following initial cohort receive cell transplant unilaterally lumbar spinal cord , subsequent cohort receive escalate dos transplant unilaterally cervical spinal cord . Subjects outcome measure assessor blind side treatment . The study conduct site extensive clinical experience care patient ALS . The study plan enroll 30 subject 24 month . Each subject receive single time point administration Q-Cells® : 5 10 ( dependent upon dose level ) transplantation focus target anterior horn either lumbar cervical spinal cord . The study consist Screening , Pre-operative/Treatment , Post-treatment study period . The study data assess safety efficacy last subject complete 9-month study visit . Following 9-month study period , subject consent continue follow safety efficacy long-term separate protocol .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>1 . Subject ability understand purpose risk study provide sign date informed consent authorization collect use protect health information ( PHI ) accordance national local subject privacy regulation . 2 . Subject life within reasonable drive distance study center ( approximately 3 hour ) . 3 . Subject caregiver willing/able assist transportation care require study participation . 4 . Subject 18 80 year age ( inclusive ) first day Screening Period . 5 . Subject diagnose sporadic familial ALS within past 48 month . 6 . Subject meet laboratorysupported probable , clinically probable , definite criterion diagnose ALS accord World Federation Neurology El Escorial criterion . 7 . Subject upright FVC ≥65 % predict value age , height , gender Screening . 8 . Subject take riluzole least 30 day prior first day Screening Period , stable dose riluzole least 30 day prior first day Screening Period ( Riluzolenaïve subject permit study ) . 9 . Subject medically able undergo study procedure physically able adhere visit schedule time study entry . 10 . Women childbearing capacity must negative pregnancy test Screening Period PreOperative Visit . 11 . Subject must agree practice effective birth control study participation . 1 . Subject cause neuromuscular weakness ALS practically exclude . 2 . Subject diagnosis significant cognitive impairment , clinical dementia , major psychiatric illness include psychosis , bipolar disease , major depression , determine DSMV . 3 . Subject diagnosis neurodegenerative disease ( e.g. , Parkinson 's disease , Alzheimer 's disease ) . 4 . Subject diagnosis medical condition impairs nerve muscle function ( e.g. , notable peripheral neuropathy , metabolic muscle disease ) . 5 . Subject clinically significant history unstable cardiac , pulmonary , renal , hepatic , endocrine , hematologic , active malignancy infectious disease medically significant illness , , opinion Investigator , would preclude study participation . 6 . Subject history spine surgery anatomic variation incompatible route administration ( determined neurosurgeon ) . 7 . Subject severe cervical lumbar stenosis , cord compression , cervical lumbar myelopathy . 8 . Subject abnormal flow void surface spinal cord suggestive arteriovenous malformation ( AVM ) . 9 . Subject demonstrate evidence CNS malignancy CNS lesion define image study CNS ( MRI brain spinal cord ) . 10 . Subject uncontrolled hypertension ( Systolic BP &gt; 180mmHg and/or Diastolic BP &gt; 110mmHg ) history thrombotic event poorly control medical condition , opinion Investigator and/or surgeon , increase risk surgery . 11 . Subject undergo MRI examination presence pacemaker , implant defibrillator certain implanted electronic metallic device , might expose metal fragment , reason subject undergo MRI routinely duration trial . 12 . Subject clinically significant abnormal clinical laboratory value , determine Investigator Screening Period . 13 . Subject immune compromise condition contraindicate treatment immunosuppression agent ( e.g. , tuberculosis , latent infection ) . 14 . Subject aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) value &gt; 3.0 time upper limit normal creatinine &gt; 1.5 time upper limit normal and/or eGFR &lt; 50cc/min Screening Period . 15 . Subject history alcohol drug abuse dependence within 1 year first day Screening Period , per DSMV criterion . 16 . Subject unlikely comply study requirement , determine Investigator . 17 . Subject expose experimental agent ( offlabel use investigational ) within 30 day first day Screening Period . Biologic agent may need additional time washout evaluate Sponsor casebycase basis . 18 . Subject previously administer stem cell . 19 . Subject preexist antihuman leukocyte antigen ( HLA ) class I class II antibody direct QCells® , determine panel reactive antibody ( PRA ) assay Screening Period . 20 . Subject allergy QCells® constituent ( e.g. , chicken egg ) , allergy coadministered immunosuppressant excipients . 21 . Subject medical condition use concomitant medication would contraindicate use tacrolimus , mycophenolate mofetil , prednisone determine Investigator . 22 . Subject evidence deep vein thrombosis ( DVT ) venous ultrasound previous evidence DVT . 23 . Subject , opinion Investigator , take take concomitant medication , supplement , agent may interfere safety evaluation QCells® may affect course subject 's ALS progression .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>